🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Sponsor trial record
Trackers Companies Trial finder
Sponsor · clinical trials

Sichuan Provincial People's Hospital clinical trials

Source: ClinicalTrials.gov, U.S. National Library of Medicine — current trials in our China register with Sichuan Provincial People's Hospital as lead sponsor. Synced 26 Sep 2026
19Current trials
11Recruiting now
7Drugs in these trials
1Trial register
Maintained by Sreepriya Prasannan
MSc Digital Transformation of Life Sciences (Innopharma Education / Griffith College); MSc & BSc Botany HSE Spark Ignite 2026 — Top 14 finalist
Compiled from ClinicalTrials.gov and CTIS registry records · Last verified · Editorial standards
At a glance

Sichuan Provincial People's Hospital is the lead sponsor of 19 current clinical trials in our China register. 11 are recruiting patients now. The most common phase is Observational. The drugs named most often in its trials are Aspirin, Atorvastatin Calcium and CM313. The most-studied condition is Acute Ischemic Stroke.

ClinicalTrials.gov trials by status

  • Recruiting1158%
  • Not yet open737%
  • By invitation15%

Trials by phase

  • Observational842%
  • Not applicable632%
  • Phase 4316%
  • Phase EARLY_PHASE115%
  • Phase 315%
01

Clinical trials sponsored by Sichuan Provincial People's Hospital

19 on ClinicalTrials.gov
StudyPhaseStatusStartRegisters
Sulbactam-Durlobactam in CRAB Infection: A Real-World Cohort Study
NCT07601711 · ClinicalTrials.gov ↗ · Carbapenem-Resistant Acinetobacter Baumannii Infection, Bloodstream Infection, Pneumonia
Observational Recruiting 2025-11 China
A Multi-center Open Label Prospective Study on Early Initiation of Targeted-release Formulation of Budesonide in Patients With Primary IgA Nephropathy
NCT06676007 · ClinicalTrials.gov ↗ · IgA Nephropathy (IgAN), Early Initial Therapy
Observational Recruiting 2024-10 China
Titration of Inspired Oxygen to Decrease the Incidence of Postoperative Pulmonary Complications
NCT06243146 · ClinicalTrials.gov ↗ · Unrecognized Condition
Not applicable Recruiting 2024-06 China
Mechanism of Red Yeast Rice Regulating Intestinal Indole Metabolism Pathway to Improve Chronic Inflammation in Polycystic Ovary Syndrome
NCT07106996 · ClinicalTrials.gov ↗ · Polycystic Ovary Syndrome (PCOS)
Phase EARLY_PHASE1 Recruiting 2025-07 China
Study on the Effect of Fecal Microbiota Transplantation on Eradication of Refractory Helicobacter Pylori Infection
NCT07704255 · ClinicalTrials.gov ↗ · Helicobacter Pylori Infection
Phase 4 Recruiting 2026-07 China
Prone Positioning in ARDS: Predicting Neurological Complications Via Cerebral Hemodynamics
NCT06967285 · ClinicalTrials.gov ↗ · ARDS (Moderate or Severe)
Observational Recruiting 2025-03 China
Precision Antiplatelet Therapy Guided by Platelet Aggregation Function in Patients With Acute Ischemic STROKE
NCT06853535 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke, Clopidogrel Resistance
Phase 3 Recruiting 2025-05 China
Nursing Interventions for Alzheimer's Patients During PET/CT Imaging
NCT06784830 · ClinicalTrials.gov ↗ · Alzheimer's Disease
Not applicable Recruiting 2024-06 China
Efficacy and Safety of Amphotericin B and Azoles in the Treatment of Invasive Fungal Disease
NCT06819410 · ClinicalTrials.gov ↗ · Invasive Fungal Disease
Observational Recruiting 2021-05 China
Efficacy and Safety of Cocktail of Ropivacaine for Local Infiltration Analgesia in Patients Undergoing Laparoscopic Cholecystectomy
NCT06819748 · ClinicalTrials.gov ↗ · Cholecystectomy, Laparoscopic, Ambulatory Surgical Procedures, Multimodal Analgesia
Not applicable Recruiting 2025-02 China
[18F]AV45(Aβ) and [18F]AV1451(Tau)PET/CT in the Diagnosis of Early Pathological Changes of Alzheimer's Disease
NCT06833645 · ClinicalTrials.gov ↗ · Alzheimer's Disease
Observational Recruiting 2024-05 China
Intracranial Hemorrhage Risk of Intensive Statin in Acute Ischemic Stroke With Cerebral Microbleeds
NCT05589454 · ClinicalTrials.gov ↗ · Acute Ischemic Stroke, Cerebral Microbleeds
Phase 4 Not yet open 2023-01 China
A Single-center Study of CM313 in Patients With Pemphigus
NCT06904040 · ClinicalTrials.gov ↗ · Pemphigus
Drug: CM313
Not applicable Not yet open 2025-04 China
Investigating the Retardation Effect of OCTA-Guided Targeted Photocoagulation on the Progression of Non-Perfusion Areas in Diabetic Retinopathy Patients
NCT06821633 · ClinicalTrials.gov ↗ · Diabetic Retinopathy
Not applicable Not yet open 2025-07 China
Muscle Ultrasound for Sarcopenia Assessment in Kidney Transplant Recipients
NCT07607236 · ClinicalTrials.gov ↗ · Sarcopenia, Kidney Transplantation, Muscle Wasting
Observational Not yet open 2026-05 China
Liposomal Amphotericin B for Invasive Fungal Disease in Solid Organ Transplant Recipients
NCT07656493 · ClinicalTrials.gov ↗ · Invasive Fungal Infection, Solid Organ Transplantation, Opportunistic Infections
Observational Not yet open 2026-07 China
Safety and Efficacy of Connecting the Residual Ear to the Cartilage Scaffold in First- vs. Second-Stage Surgery
NCT06763991 · ClinicalTrials.gov ↗ · Microtia, Outcome Assessment, RCT
Not applicable Not yet open 2025-06 China
Platelet Aggregation Function-Guided De-Escalation Antiplatelet Therapy in Patients With Acute Ischemic Stroke
NCT07644234 · ClinicalTrials.gov ↗ · Ischemic Stroke, Transient Ischemic Attack
Phase 4 Not yet open 2026-06 China
18F-MFBG Cardiac Imaging for Heart Failure Administration
NCT06149195 · ClinicalTrials.gov ↗ · Rest Gated Myocardial Perfusion Imaging in Heart Failure
Observational By invitation 2024-01 China

Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Titles and statuses are copied from the registry as published.

02

Drugs in Sichuan Provincial People's Hospital trials

7 compounds

Drugs and biologicals named as interventions in these trials, with the number of this sponsor's trials that name each one. Placebos and generic comparators are excluded.

03

Conditions in Sichuan Provincial People's Hospital trials

33 conditions
Acute Ischemic Stroke2Alzheimer's Disease2Carbapenem-Resistant Acinetobacter Baumannii Infection1Bloodstream Infection1Pneumonia1Sepsis1IgA Nephropathy (IgAN)1Early Initial Therapy1Cerebral Microbleeds1Pemphigus1Rest Gated Myocardial Perfusion Imaging in Heart Failure1Unrecognized Condition1Diabetic Retinopathy1Polycystic Ovary Syndrome (PCOS)1Helicobacter Pylori Infection1ARDS (Moderate or Severe)1Sarcopenia1Kidney Transplantation1Muscle Wasting1Invasive Fungal Infection1Solid Organ Transplantation1Opportunistic Infections1Clopidogrel Resistance1Microtia1
04

By trial register

RegisterTrialsRecruiting
Clinical trials in China1911

A trial with sites in more than one country appears in each of those registers.

05

Other sponsors in Acute Ischemic Stroke

SponsorTrials
Capital Medical University14
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University7
Xuanwu Hospital, Beijing6
Nanfang Hospital, Southern Medical University4
Beijing Anzhen Hospital4
Yi Yang4
The First Affiliated Hospital of University of Science and Technology of China4
The First Affiliated Hospital of Zhengzhou University3
Xiang Luo3
Shanghai Pharmaceuticals Holding2

Sponsors with the most current trials registered for this condition.

06

Questions about Sichuan Provincial People's Hospital trials

How many clinical trials does Sichuan Provincial People's Hospital sponsor?

Sichuan Provincial People's Hospital is the lead sponsor of 19 current trials on ClinicalTrials.gov in our China register, as of the registry sync on 26 September 2026. Completed and withdrawn studies are not counted.

Are Sichuan Provincial People's Hospital trials recruiting?

Yes. 11 of its 19 ClinicalTrials.gov trials are recruiting. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.

Which drugs is Sichuan Provincial People's Hospital testing?

Its current trials name 7 drugs and biologicals as interventions. The most frequent are Aspirin (1), Atorvastatin Calcium (1), CM313 (1), Clopidogrel (1) and Liposomal Amphotericin B (1). The number in brackets is how many of its trials name each drug.

Where does this information come from?

Every trial, status, phase and condition on this page is copied from public ClinicalTrials.gov and EU CTIS records by a daily sync, grouped by the sponsor name each registry records. It says nothing about the organisation beyond its registered trials, and it is not medical advice.

Approvals, shortages and trials, every Friday

One email a week with new EMA and FDA approvals, EU and US medicine shortages, how many trials are recruiting in Ireland, and the week's Irish pharma news.

Free. Unsubscribe from any email with one click. See our privacy policy.

How this page is built

Everything on this page is copied from public registry records — it is not written from memory, and nothing here describes the organisation beyond its registered trials. Each trial links to its own record so you can check it yourself.

This page is built automatically: a daily sync job reads the registry records behind our trial registers and groups every current trial by its lead sponsor name, ignoring legal-form suffixes such as Inc. or Ltd. A small, hand-checked list joins the same organisation's different registry names (for example its EU legal entity). There is no AI drafting and no per-sponsor editorial pass. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The the registries data on this page was last retrieved on 26 Sep 2026.

Please verify before you rely on this. This page is general information for life-science and pharmaceutical professionals. It is not medical advice, and it has not been reviewed by a clinician — our editorial team holds life-science qualifications, not clinical ones. It is not exhaustive and may not reflect the most recent label change. Always check the official prescribing information (US Prescribing Information or EU SmPC) and speak to your doctor or pharmacist before acting on anything here. Drugs in the same class are not automatically interchangeable, and approvals, brand names and indications differ between the US, the EU/Ireland (EMA/HPRA) and other regions. Spotted an error? Tell us — we correct promptly and log it.